Cialis, Ambien CR top sites driving prescription requests, study says

Share this article:
Lilly Icos’ Cialis was identified as the pharmaceutical product site with the highest percent of visitors requesting a prescription after visiting, a new study says. Cialis was followed by Pfizer’s Viagra, AstraZeneca’s Nexium, Sepracor’s Lunesta and Sanofi-Aventis’ Allegra respectively, according to the results of the study conducted by market research firm Manhattan Research. The study, titled ePharma Consumer v6.0: The Future of Integrated DTC Marketing, provides data on over 100 pharmaceutical product sites and consumer actions as polled from 4,965 US adults. The Manhattan Research study further identified Sanofi-Aventis’ Ambien CR Web site as the top Rx product site driving prescription requests after visiting the site by prescription volume. Ambien CR was followed by Sanofi-Aventis’ Allegra, GlaxoSmithKline’s Wellbutrin XL, Sepracor’s Lunesta and AstraZeneca’s Lunesta respectively. Further details of the ePharma Consumer v6.0 study will be made available during a Webinar being offered by Manhattan Research today.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...